MedTrace Logo

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

NCT06895499 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.

Conditions

Interventions

DRUG

HB0043

Low dose

DRUG

HB0043

Medium dose

DRUG

HB0043

High dose

Sponsors & Collaborators

  • Dermatology Hospital affiliated to Shandong First Medical University

    collaborator UNKNOWN

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-19
Primary Completion
2026-01-30
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06895499 on ClinicalTrials.gov